Bittner S, et al. Biosensors for inflammation as a strategy to engineer regulatory T cells for cell therapy. Proc Natl Acad Sci USA. 2022;119(40): e2208436119.

PubMed  PubMed Central  Google Scholar 

Glaubitz J, et al. In mouse chronic pancreatitis CD25+ FOXP3+ regulatory T cells control pancreatic fibrosis by suppression of the type 2 immune response. Nat Commun. 2022;13(1):4502.

PubMed  PubMed Central  Google Scholar 

Ichikawa T, et al. CD103hi treg cells constrain lung fibrosis induced by CD103lo tissue-resident pathogenic CD4 T cells. Nat Immunol. 2019;20(11):1469–80.

PubMed  Google Scholar 

Lamarche C, et al. Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion. Proc Natl Acad Sci USA. 2023;120(14): e2219086120.

PubMed  PubMed Central  Google Scholar 

Burton BR, et al. Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nat Commun. 2014;5(1):4741.

PubMed  Google Scholar 

Gerace D, et al. Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance. Cell Rep Med. 2023. https://doi.org/10.1016/j.xcrm.2022.100879.

PubMed  PubMed Central  Google Scholar 

Mortezaee K. Normalization in tumor ecosystem: opportunities and challenges. Cell Biol Int. 2021;45(10):2017–30.

PubMed  Google Scholar 

Oliveira G, et al. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature. 2022;605(7910):532–8.

PubMed  PubMed Central  Google Scholar 

Wu Q, et al. Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment. Hepatology. 2023. 10.1097.

Geels SN, et al. Interruption of the intratumor CD8+ T cell: Treg crosstalk improves the efficacy of PD-1 immunotherapy. Cancer Cell. 2024;42(6):1051-1066. e7.

PubMed  PubMed Central  Google Scholar 

Rodrigues M, et al. Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial. Nat Commun. 2023;14(1):3698.

PubMed  PubMed Central  Google Scholar 

Handgraaf SM, Akkari L. Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors. Berlin: Nature Portfolio; 2023.

Google Scholar 

Oshi M, et al. Clinical relevance of intra-tumoral density of regulatory T cells as a predictive factor for chemotherapy response in metastatic colorectal cancer. Cancer Res. 2022;82(12 Supplement):6112–6112.

Google Scholar 

Chao JL, et al. Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma. Cell Rep Med. 2021. https://doi.org/10.1016/j.xcrm.2021.100399.

PubMed  PubMed Central  Google Scholar 

Huang C, et al. PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance. Sci Adv. 2023;9(21): eade4186.

PubMed  PubMed Central  Google Scholar 

Amoozgar Z, et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun. 2021;12(1):2582.

PubMed  PubMed Central  Google Scholar 

Kim MJ, et al. Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells. Nat Immunol. 2023;24(1):148–61.

PubMed  Google Scholar 

Kamada T, et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA. 2019;116(20):9999–10008.

PubMed  PubMed Central  Google Scholar 

Dykema AG, et al. Lung tumor-infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response. Sci Immunol. 2023;8(87): eadg1487.

PubMed  PubMed Central  Google Scholar 

van der Leun AM, et al. Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T-cell and activated Treg compartment. Cancer Discov. 2023;13(10):2212–27.

PubMed  PubMed Central  Google Scholar 

van Pul KM, et al. Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation. Sci Immunol. 2022;7(73): eabn8097.

PubMed  Google Scholar 

Wing JB, Ise W, Kurosaki T, Sakaguchi S. Regulatory t cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity. 2014;41(6):1013–25.

PubMed  Google Scholar 

Marangoni F, et al. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. Cell. 2021;184(15):3998-4015. e19.

PubMed  PubMed Central  Google Scholar 

Yofe I, et al. Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling. Nat Cancer. 2022;3(11):1336–50.

PubMed  Google Scholar 

Cohen Saban N, et al. Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy. Sci Immunol. 2023;8(81): eadd8005.

PubMed  Google Scholar 

Li J, et al. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. Cancer Cell. 2023. https://doi.org/10.1016/j.ccell.2023.04.011.

PubMed  PubMed Central  Google Scholar 

van Gulijk M, et al. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Sci Immunol. 2023;8(83):eabn6173.

PubMed  Google Scholar 

Zhang Y, et al. Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. Cancer Discov. 2020;10(3):422–39.

PubMed  PubMed Central  Google Scholar 

Glasner A, et al. Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies. Nat Immunol. 2023;24(6):1020-1035.

Shi LZ. Trimming the “fatty” intratumoral Tregs for cancer immunotherapy. Sci Transl Med. 2020;12(534): eabb2770.

Google Scholar 

Mortezaee K. Organ tropism in solid tumor metastasis: an updated review. Future Oncol. 2021;17(15):1943–61.

PubMed  Google Scholar 

Boreddy SR, et al. BCA101 is a tumor-targeted bifunctional fusion antibody that simultaneously inhibits EGFR and TGFβ signaling to durably suppress tumor growth. Cancer Res. 2023;83(11):1883–904.

PubMed  PubMed Central  Google Scholar 

Shi L, Lim JY, Kam LC. Substrate stiffness enhances human regulatory T cell induction and metabolism. Biomaterials. 2023;292: 121928.

PubMed  Google Scholar 

Montauti E, et al. A deubiquitination module essential for Treg fitness in the tumor microenvironment. Sci Adv. 2022;8(47): eabo4116.

PubMed  PubMed Central  Google Scholar 

Lainé A, et al. Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation. Nat Commun. 2021;12(1): 6228.

PubMed  PubMed Central  Google Scholar 

Li L, et al. Laminin γ2-mediating T cell exclusion attenuates response to anti-PD-1 therapy. Sci Adv. 2021;7(6): eabc8346.

PubMed  PubMed Central  Google Scholar 

Zhou M, et al. Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy. Nat Commun. 2023;14(1):3593.

PubMed  PubMed Central  Google Scholar 

Chen J, et al. TGF-β1-induced SOX18 elevation promotes hepatocellular carcinoma progression and metastasis through transcriptionally upregulating PD-L1 and CXCL12. Gastroenterology. 2024;167(2):264–80.

PubMed  Google Scholar 

Luo X, et al. SOX12 facilitates hepatocellular carcinoma progression and metastasis through promoting regulatory T-cells infiltration and immunosuppression. Adv Sci. 2024;11(36):2310304.

Google Scholar 

Shen Y, et al. Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation. Nat Commun. 2022;13(1):3419.

PubMed  PubMed Central  Google Scholar 

Strait AA, et al. Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma. Commun Biol. 2021;4(1):1005.

PubMed  PubMed Central  Google Scholar 

Sievers C, et al. Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer. Cancer Cell. 2023;41(5):887-902. e5.

PubMed  PubMed Central  Google Scholar 

Karami Z, Mortezaee K, Majidpoor J. Dual anti-PD-(L) 1/TGF-β inhibitors in cancer immunotherapy—updated. Int Immunopharmacol. 2023;122: 110648.

PubMed  Google Scholar 

Jiang R, et al. The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nat Commun. 2017;8(1):15129.

PubMed  PubMed Central  Google Scholar 

Sugiyama E, et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. Sci Immunol. 2020;5(43): eaav3937.